Le produit a bien été ajouté au panier.

discount label
H-GWEPDDNPI-OH
Vue en 3D

Biosynth logo

H-GWEPDDNPI-OH

Ref. 3D-PP43614

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Livraison estimée en/au États-Unis, le vendredi 27 décembre 2024

Informations sur le produit

Nom :
H-GWEPDDNPI-OH
Synonymes :
  • NH2-Gly-Trp-Glu-Pro-Asp-Asp-Asn-Pro-Ile-OH
Description :

Peptide H-GWEPDDNPI-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-GWEPDDNPI-OH include the following: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression XT Song , KE Kabler, L Shen, L Rollins, XF Huang - Nature medicine, 2008 - nature.comhttps://www.nature.com/articles/nm1721 Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity V Rigo, MV Corrias, AM Orengo, A Brizzolara - Cancer Immunology , 2014 - Springerhttps://link.springer.com/article/10.1007/s00262-014-1536-9 Survivin minigene DNA vaccination is effective against neuroblastoma S Fest, N Huebener, M Bleeke - journal of cancer, 2009 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.24291 Cry1Ac Protoxin Confers Antitumor Adjuvant Effect in a Triple-Negative Breast Cancer Mouse Model by Improving Tumor Immunity RR Servin-Garrido - Cancer: Basic and , 2022 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.1177/11782234211065154 Treat cancers by targeting survivin: just a dream or future reality? MS Coumar , FY Tsai, JR Kanwar , S Sarvagalla - Cancer treatment , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0305737213000339 Checkpoint blockade in combination with cancer vaccines MA Morse, HK Lyerly - Vaccine, 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X15014723 Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen M Croce , R Meazza, AM Orengo, M Fabbi - Cancer Immunology , 2008 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0496-3 Neuroblastoma: Perspectives for the Use of IL-21 in Immunotherapy M Croce , MV Corrias, S Ferrini - Neuroblastoma: Diagnosis, Therapy, and , 2012 - Springerhttps://link.springer.com/chapter/10.1007/978-94-007-2418-1_12 Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models K Zhu, H Qin, SC Cha, SS Neelapu , W Overwijk - Vaccine, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X07009929 Aedes aegypti midgut DNA synthesis de novo is an essential antiviral strategy against dengue virus serotype 2 replication J Serrato - IMMUNO MEXICO 2018 - academia.eduhttps://www.academia.edu/download/108101289/ALAI_SMI_IMUNOMEXICO_2018.pdf#page=1030 Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model EL Williams, SN Dunn, S James, PW Johnson - Clinical cancer , 2013 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/19/13/3545/207430 Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha E Balza , B Carnemolla, L Mortara - journal of cancer, 2010 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.25018 STING Ligand c-di-GMP Improves Cancer Vaccination D Chandra, AJ Wilber Quispe-Tintaya - academia.eduhttps://www.academia.edu/download/35121430/Chandra_STING_ligand_improve_cancer_vaccine.pdf STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer D Chandra , W Quispe-Tintaya , A Jahangir - Cancer immunology , 2014 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/2/9/901/467559 Excreted/secreted products from a helminth parasite inhibits tumorigenesis on the early stages of colitis associated colorectal cancer BEC Piaca±a, SR Martaca­nez, I Chavez, CDacaSB Soto - IMMUNO MEXICO - researchgate.nethttps://www.researchgate.net/profile/Elizabeth_Salinas_Estrella/publication/328389976_Antibodies_generated_against_bovine_CD205_using_a_bioinformatics_approach/links/5bca0548458515f7d9cb8310/Antibodies-generated-against-bovine-CD205-using-a-bioinformatics-approach.pdf#page=1042 Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of A NoeDominguez-Romero - Human Vaccines & , 2014 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/hv.29679 Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms A Jahangir , D Chandra , W Quispe-Tintaya - , 2017 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2017.1342025 Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model A de Jesus Jimenez-Chavez , L Moreno-Fierros - Vaccine, 2019 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X19312964

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP43614 H-GWEPDDNPI-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".